CJC1295 With DAC Powder CAS:446262-90-4

    What is CJC-1295?

    CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) that was developed in the mid-2000s by ConjuChem Technologies. Originally designed to treat obesity issues in HIV/AIDS patients, the peptide has since been shown to effectively treat growth hormone deficiency, improve sleep quality, and promote longevity, and is classified as a prohibited substance under Section S2 of the World Anti-Doping Agency's (WADA) Prohibited List.

    While standard CJC-1295 peptide is made up of 29 amino acids, it is most commonly available as CJC-1295 DAC, which stands for "Drug Affinity Complex." DAC is a bioconjugation platform that improves the ability of the CJC-1295 peptide to bond with blood protein, giving it a much longer half-life than regular CJC-1295.

    Confusion has arisen because the original CJC-1295 from ConjuChem Technologies contained DAC, yet other manufacturers subsequently began producing CJC-1295 without DAC. To clear up this confusion, CJC-1295 that does not contain DAC is typically labeled as "CJC-1295 Without DAC" or "CJC-1295 No DAC".

    All references to CJC-1295 herein are references to CJC-1295 with the added DAC technology developed by ConjuChem.

    At the time of writing, there are no FDA-approved products containing CJC-1295, and the peptide is classed as an Investigational New Drug in the United States, available exclusively to researchers as a reference material.

    CJC-1295 binds to receptors in the pituitary gland to stimulate the release of growth hormones plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Its mechanism of action is similar to sermorelin in that it raises GH levels and acts on the GHRH receptor. However, CJC-1295 takes longer than sermorelin to clear from the body and exhibits longer periods of high GH, whereas sermorelin creates a more natural release of GH.

    The half-life of CJC-1295, which selectively binds to endogenous albumin, is extended considerably by the addition of DAC. CJC-1295 No DAC has a half-life of just thirty minutes, while CJC-1295 DAC has an estimated half-life of 6 to 10 days.

    Animal studies have confirmed that CJC-1295 acts as a long-lasting GRF analog and can activate the GRF receptors on the anterior pituitary in rats. Based on this research, several studies have investigated the effect of CJC-1295 on GH and IGF-1 in various animal models.

    While we have limited human data on CJC-1295, we can nonetheless draw on small-scale studies and animal research to summarize the key CJC-1295 benefits observed to date:

    CJC-1295 may promote deep sleep: Several studies have suggested that GHRH plays a direct role in improving the quality of sleep. As      CJC-1295 is a synthetic analogue of GHRH, there is strong research interest in the role it may play in sleep.

    Fehm et al. investigated intranasal administration of GHRH and documented the effect it had on sleep quality. The study was performed according to a double-blind cross-over design and involved 12 young and 11 old healthy male test subjects, each of whom were intranasally administered 300 micrograms GHRH or placebo 30 min before bedtime.

    Sleep was recorded polysomnographically until 7 am and blood was collected in 15 minute intervals for determination of cortisol and GH. Apart from the well-known age-related changes in hormonal secretion and sleep, intranasal GHRH had the following effects:

    ●Reduced cortisol nadir concentrations at the beginning of sleep (P < 0.05)

    ●Reduction in sleep-induced elevation in GH concentrations during early sleep

    ●Increased rapid-eye-movement (REM) sleep

    ●Increased slow-wave sleep (SWS), with this influence concentrating on the second half of sleep time

    Based on these findings, intranasal GHRH appears to help regulate sleep processes and hypothalamic-hypophysiotropic secretory activity in both young and elderly male test subjects. This suggests that GHRH mimics the dual neuronal and endocrine function of hypothalamic GHRH activity.

    Sleep helps recovery from muscle injury [9]. GH has been shown to enhance non-REM sleep after a period of sleep deprivation. As a GHRH analogue, CJC-1295 is being actively investigated for its potential to produce deep, restorative sleep in subjects.

---

    CJC-1295 may increase muscle mass: CJC-1295's documented ability to increase levels of GH and IGF-1 has prompted research interest in the role that it may play in increasing muscle mass. CJC-1295 stimulates protein synthesis and supports muscle mass growth. While research in this area is ongoing, it remains to be determined whether healthy subjects may receive anabolic benefit from increased GH and IGF-1.
    Researchers interested in exploring CJC-1295's purported effect on muscle mass may consider a blend of CJC-1295 and ipamorelin. This peptide combination has been linked to increased protein synthesis and muscle mass growth.

---

    CJC-1295 may stimulate fat loss: Studies have shown that prolactin promotes visceral fat accrual in various animal models [12] and that CJC-1295 can normalize prolactin levels as shown in GHRH knockout mice, which can lead to increased fat metabolization. These findings have led to strong research interest in the role that CJC-1295 may play in fat loss through prolactin regulation.

    Researchers interested in exploring CJC-1295's purported ability to stimulate fat loss may consider a blend of CJC-1295 and GHRP-2. GHRP-2 also stimulates GH release from the anterior pituitary by acting on a different receptor to CJC-1295, called the growth hormone secretagogue receptor (GHSR). Studies in animal models have shown that GHRP-2 has a positive effect on muscle mass, heart function, and the immune system, suggesting that it may work synergistically when administered with CJC-1295.

    In the early days of CJC-1295's development, ConjuChem tested CJC-1295 as a potential treatment for HIV-associated lipodystrophy. One of the patients in the study died, though the attending physician concluded that the cause was not due to CJC-1295 administration .

    The most common self-reported side effects of CJC-1295 are:

    ●Flu-like symptoms

    ●Headaches

    ●Irritability

    ●Anxiety

    ●Nausea

    While several short-term studies involving CJC-1295 indicate that this peptide has a positive safety profile, long-term studies are lacking and further research is needed to confirm its safety.

    A key safety concern among researchers is that CJC-1295 has an extremely long half-life of 6-10 days. This means that it does not have a natural model of action and may potentially cause unwanted side effects during long-term administration.

    Clearly, a well-designed phase 1 safety study with independent validation would be required before drawing any conclusions.

    Concerning CJC-1295 dosage, researchers may refer to the two 2006 studies by Teichman et al., which involved healthy test subjects aged 21-61 and followed a randomized, placebo-controlled, double-blind, ascending dose design .

    In the first study, which lasted 28 days, CJC-1295 or placebo was administered in one of four ascending single doses.

    In the second study, which lasted 49 days, test subjects received CJC-1295 or placebo in two or three weekly or biweekly doses.

    After measuring the peak concentrations and area under the curve of GH and IGF-1, researchers found that CJC-1295 increased mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and increased mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days.

    Studies suggest that CJC-1295 boosts GH and IGF-I levels in healthy adults and is tolerated in a dose range of 30-60 μg/kg

    Top peptide researchers know that a lab is not complete without the right set of ancillary tools for the correct preparation, storage, and handling of peptides, including CJC-1295.

    What does this list of supplies include? Items like bacteriostatic water, sterile vials, and alcohol wipes are indispensable.

    Usually, a research lab may need supplies and materials like:

    ●Bacteriostatic Water

    ●Insulin Syringes

    ●Sterile Empty Glass Vials

    ●Large Needles + Syringes

    ●Alcohol Prep Pads

    CJC-1295 has demonstrated potential as a growth hormone-releasing hormone analogue that stimulates both GH and IGF-1 for a prolonged period of six to ten days, thanks to the addition of ConjuChem's DAC technology.

    As higher levels of both GH and IGF-1 have been linked to performance-enhancing effects such as increased muscle mass, better sleep, and decreased fat, CJC-1295 remains firmly on the radar of peptide researchers.

Trade names	DAC,GRF
CAS	446262-90-4
Molar mass	3367.954
Formula	C152H252N44O42
Purity	Above 98%
Apprarance	White crystalline powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-19128233885

   

                                

 

    How to take CJC-1295?
    CJC-1295 is available in the form of powder and must be reconstituted using bacteriostatic or sterile water.

 

    How is CJC-1295 delivered?

    After being reconstituted, CJC-1295 is administered subcutaneously.

 

    How to reconstitute CJC-1295?

    CJC-1295 is reconstituted with bacteriostatic water.

 

    Is CJC-1295 legal?

    Qualified researchers may legally purchase CJC-1295 as a reference material for in vitro experimentation. At this time, CJC-1295 is not sold to the general public or intended for human use.

 

    Is CJC-1295 legit?

    CJC-1295 has been shown to increase GH and IGF-1 levels in test subjects and is of interest to researchers interested in its effects on body composition, anti-aging, and sleep, among other applications.

 

    Is CJC-1295 a steroid?

    No, CJC-1295 is not an anabolic-androgenic steroid. It is a synthetic analogue of GHRH and growth hormone secretagogue (GHS).

 

    Does CJC-1295 increase testosterone?

    No, CJC-1295 increases serum levels of GH and IGF-I, but does not increase testosterone.

 

    Does CJC-1295 build muscle?

    Administration of CJC-1295 is associated with sustained, dose-dependent increases in GH and IGF-I levels in healthy subjects [16], by consequence of which CJC-1295 may have a role in increasing muscle mass.

 

    Does CJC-1295 cause weight gain?

    No, there is no evidence that CJC-1295 administration directly causes weight gain. One the other hand, research indicates that CJC-1295 may stimulate fat loss through prolactin regulation.

 

 

 

 

Hot Tags: cjc1295 with dac powder cas:446262-90-4, China cjc1295 with dac powder cas:446262-90-4 manufacturers, suppliers, factory